Asset Details
Do you wish to reserve the book?
A Randomized Trial of Directly Administered Antiretroviral Therapy and Adherence Case Management Intervention
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A Randomized Trial of Directly Administered Antiretroviral Therapy and Adherence Case Management Intervention
Do you wish to request the book?
A Randomized Trial of Directly Administered Antiretroviral Therapy and Adherence Case Management Intervention
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A Randomized Trial of Directly Administered Antiretroviral Therapy and Adherence Case Management Intervention
2006
Overview
Background. A randomized, controlled trial was conducted to evaluate the impact of a directly administered antiretroviral therapy program (DAART) and intensive adherence case management (IACM) intervention on virologic and immunologic response to highly active antiretroviral therapy (HAART) among patients at 3 public human immunodeficiency virus clinics in Los Angeles County, California. Methods. Participants included 250 treatment-naive and treatment-experienced persons for whom no more than 1 prior HAART regimen had failed. Five days per week for 6 months, a community worker delivered 1 HAART dose to DAART participants and observed the participant take it. IACM participants met weekly with a case manager to overcome barriers to HAART adherence. A control group (the standard of care [SOC] group) received the usual care. Results. The majority of patients were Latino (64%) or African American (24%); 57% were monolingual Spanish speakers. Seventy-five percent of the patients were male, and 64% reported an annual income of <$10,000. In an intent-to-treat analysis, no statistical differences were observed in the percentage of patients with an undetectable viral load (i.e., <400 copies/mL) at 6 months between the DAART group (54%), IACM group (60%), and SOC group (54%; P > .05). An on-treatment analysis determined that there were no statistical differences in the percentage of patients with an undetectable viral load at 6 months between the DAART group (71%), IACM group (80%), and SOC group (74%; P > .05). Additionally, there were no statistical differences in 6-month changes in the CD4+ cell count or in self-reported adherence to therapy. Conclusions. Among patients with limited prior HAART experience and adherence barriers that had not been assessed before randomization, no differences were found in virologic or immunologic response for DAART or IACM, compared with SOC, at 6 months. DAART and IACM did not improve short-term outcomes when SOC included other means of adherence support that were not controlled for by the study design.
Publisher
The University of Chicago Press,University of Chicago Press,Oxford University Press
Subject
/ AIDS
/ Anti-HIV Agents - administration & dosage
/ Anti-HIV Agents - therapeutic use
/ Antibiotics. Antiinfectious agents. Antiparasitic agents
/ Antiretroviral Therapy, Highly Active
/ Biological and medical sciences
/ Directly Observed Therapy - methods
/ Dosage
/ Female
/ Highly active antiretroviral therapy
/ HIV
/ HIV Infections - complications
/ HIV Infections - drug therapy
/ HIV/AIDS
/ Human immunodeficiency virus
/ Humans
/ Immunodeficiencies. Immunoglobulinopathies
/ Male
/ Patients
/ Pharmacology. Drug treatments
/ Viral diseases of the lymphoid tissue and the blood. Aids
/ Virology
